Kyowa Hakko And Aussie Firm Arana To Co-Develop Anti-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Japanese biotech firm Kyowa Hakko announced April 24 an agreement with the Australian firm Arana Therapeutic to co-develop a new anti-cancer drug ART104 for colorectal cancer. Kyowa Hakko plans to use its own antibody technologies to enhance drug candidate, which the companies hope enters the clinical trial phase by 2010. Arana will receive a one time payment of $4 million and up to $4 million in milestone payments. Kyowa Hakko has an option to develop and commercialize the product in some Asian markets such as Japan, South Korea, Taiwan and China. Arana will receive royalties on these sales. (Click here for more - Japanese language
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.